Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$6.98 USD
-0.04 (-0.57%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $6.99 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Astria Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ATXS 6.98 -0.04(-0.57%)
Will ATXS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATXS
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?
ATXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ATXS
Astria Therapeutics licenses navenibart rights in Japan to Kaken Pharmaceutical
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and ...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS ...
Astria: Betting On Navenibart In The Crowded HAE Arena
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National ...